Registered Attendees

Registered Attendees

Print This Page

Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online before the meeting...these abstracts will be available in the Abstract Book at the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

Close Window
Fairmont Hotel Vancouver Floorplan

Fairmont Hotel Vancouver Floorplan

Print This Page



Close Window

This meeting took place in 2013


Here are the related meetings in 2015:
Antibodies as Drugs: Immunological Scaffolds as Therapeutics (J8)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Antibodies as Drugs (J3)


Organizer(s) Paul Carter and Andreas G. Plückthun
January 27—February 1, 2013
Fairmont Hotel Vancouver • Vancouver, British Columbia Canada
Abstract Deadline: Sep 25, 2012
Late Abstract Deadline: Oct 25, 2012
Scholarship Deadline: Sep 25, 2012
Early Registration Deadline: Nov 27, 2012

Sponsored by AbbVie Inc., Astellas Pharma Inc. and Genentech, Inc. Supported by an educational donation provided by Amgen.


Summary of Meeting:
Antibodies have come of age as therapeutics since the late 1990s with 26 antibody therapeutics marketed in the USA and approximately 300 additional antibodies in clinical development. Many of these antibody drugs are targeted to malignant cells and are used for the treatment of a variety of cancers. Participants at this meeting will consider new therapeutic opportunities for antibodies and engineered targeting molecules across a broad range of clinical settings including oncology, autoimmunity and chronic inflammation, infectious diseases and neurology. Progress in molecular engineering to increase their clinical potential will be discussed including antibody-drug conjugates, bispecific and multispecific targeting molecules, effector function enhancement and half-life extension. New frontiers will be explored including engineering antibodies to cross the blood-brain barrier and tackling fundamental questions in antibody targeting, mechanisms of action and resistance, and immunogenicity of engineered proteins. This symposium will bring together experts from academia and industry, from molecular engineering to biomedical applications, at the forefront of advancing antibodies as drugs and will be of broad interest to scientists working in this area. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Cancer Immunology and Immunotherapy, which will share two plenary sessions with this meeting.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, JANUARY 27

15:00—19:30
Arrival and Registration

18:15—19:15
Refreshments

19:15—20:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Paul Carter, Genentech, Inc., USA

* Andreas G. Plückthun, University of Zürich, Switzerland

Jeffrey V. Ravetch, Rockefeller University, USA
Solving the Antibody Paradox


Following Session is for Cancer Immunology and Immunotherapy (J4)

19:15—20:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Glenn Dranoff, Dana-Farber Cancer Institute, USA

James P. Allison, HHMI/University of Texas MD Anderson Cancer Center, USA
Checkpoint Blockade


MONDAY, JANUARY 28

06:45—08:00
Breakfast

08:00—11:00
Tumor Targeting - From Understanding Mechanisms to New Targeting Agents (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Dario Neri, ETH Zürich, Switzerland

Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Synergistic Antibody and Cytokine Effects in Cancer Immunotherapy

Kerry A. Chester, University College London Cancer Institute, UK
Antibody-Targeted Nanoparticles for Cancer Treatment

Erkki Ruoslahti, Sanford-Burnham Medical Research Institute, USA
Increasing Extravasation with Peptides

Anna M. Wu, University of California, Los Angeles, USA
Engineered Antibodies for Molecular Imaging of Cancer

Henry B. Lowman, CytomX Therapeutics, Inc., USA
Short Talk: Probody™ Therapeutics: A New Class of Proteolytically Activated Antibodies

09:20—09:40
Coffee Break

11:00—13:00
Poster Setup

13:00—22:00
Poster Viewing

11:00—16:30
On Own for Lunch and Recreation

14:30—16:30
Workshop 1: Emerging Antibody Generation Methods

* James D. Marks, University of California, San Francisco, USA

Filippa Fleetwood, Royal Institute of Technology, Sweden
Surface Display of a Single-Domain Antibody Library on Gram-Positive Bacteria

Christian Kunz, MorphoSys AG, Germany
The Role of HuCAL in the Discovery of Lead Antibodies with a Unique MoA

Audrey D. McConnell, AnaptysBio, Inc., USA
High Affinity Humanized Antibodies without Making Hybridomas; Immunization Paired with Mammalian Cell Display and in vitro Somatic Hypermutation

Amandeep K. Gakhal, University of Toronto, Canada
A New Method for Direct Selection of Synthetic Antibody Fragments on Cell Surface Targets from a Phage-Displayed Library

E-Chiang Lee, Kymab Limited, UK
Development of a Next-Generation in vivo mAb Discovery Platform

Hiroshi Hamana, University of Toyama, Japan
Rabbit ISSAC (Rabbit Immunospot Array Assay on a Chip) Allows for the Rapid Generation of Rabbit Monoclonal Antibodies with High Affinity

Kai Zhu, Schrodinger Inc., USA
Ab initio Structure Prediction of the Antibody Hypervariable H3 Loop

16:30—17:00
Coffee Available

17:00—19:00
Payloaded Antibodies for Cancer Treatment
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Peter D. Senter, Seattle Genetics Inc., USA
Empowered Antibodies for Cancer Therapy

Dario Neri, ETH Zürich, Switzerland
Armed Antibodies for Vascular Targeting

Paul G. Polakis, Genentech, Inc., USA
Antibody Drug Conjugates for the Treatment of Cancer

Brian J. Agnew, Thermo Fisher Scientific, USA
Short Talk: Site-Selective Antibody Labeling without Engineering: Answering Unmet Needs in Antibody Payload Conjugation


Following Session is for Cancer Immunology and Immunotherapy (J4)

17:00—19:00
Tumor Microenvironment
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* James P. Allison, HHMI/University of Texas MD Anderson Cancer Center, USA

Wolf-Hervé Fridman, Cordeliers Research Centre, France
The Immune Microenvironment of Primary and Metastatic Human Tumors

Robert D. Schreiber, Washington University School of Medicine, USA
Cancer Immunoediting: Antigens, Mechanisms and Implications for Cancer Immunotherapy

Nikhil S. Joshi, Massachusetts Institute of Technology, USA
Short Talk: Effector Regulatory T Cell Differentiation during Autochthonous Mouse Lung Adenocarcinoma Development

Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Inflammation and Cancer

19:00—20:00
Social Hour with Lite Bites

19:30—22:00
Poster Session 1


TUESDAY, JANUARY 29

06:45—08:00
Breakfast

08:00—11:15
Antibodies in Infectious Diseases
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Human Antibodies to Infectious Disease Targets

* Dennis R. Burton, The Scripps Research Institute, USA
Broadly Neutralizing Antibodies to Identify Vaccine Targets on HIV

Gary J. Nabel, Sanofi, USA
Broadly Neutralizing Antibodies to HIV: A Model for Prevention and Treatment of an Infectious Disease

Erica Ollmann Saphire, The Scripps Research Institute, USA
Antibodies Against the Filoviruses

George Georgiou, University of Texas at Austin, USA
Proteomic Deconvolution of the Human Serological IgG Repertoire in Vaccine Evaluation and Antibody Discovery


Following Session is for Cancer Immunology and Immunotherapy (J4)

08:00—11:15
Engineering and Immunotherapy
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA

David J. Mooney, Harvard University, USA
Polymer Scaffolds for immunotherapy

Darrell J. Irvine, Massachusetts Institute of Technology, USA
Interfacing Nanoparticle Drug Carriers with Lymphocytes to Enhance Cellular Immunotherapy

Carl H. June, University of Pennsylvania, USA
Engineered T Cells for Adoptive Therapy

Hollie J. Pegram, Memorial Sloan-Kettering Cancer Center, USA
Short Talk: Expansion and Modification of Umbilical Cord Blood T Cells with a Chimeric Antigen Receptor and IL-12

Sheena N. Smith, University of Illinois at Urbana-Champaign, USA
Short Talk: Engineering Designer T Cell Receptors through the Use of Single-Chain T Cell Receptor Scaffolds

Laurence J. N. Cooper, University of Texas MD Anderson Cancer Center, USA
Sleeping Beauty Transposition for Engineered T Cells

09:20—09:40
Coffee Break

11:15—13:00
Poster Setup

13:00—22:00
Poster Viewing

11:15—16:30
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

17:00—19:00
New Technologies for Generating Proteins with Novel Functions
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Andreas G. Plückthun, University of Zürich, Switzerland

David Baker, University of Washington, USA
Computational Protein Design and Protein Therapeutics

Andrew D. Ellington, University of Texas at Austin, USA
Rational Engineering of Antibodies for Affinity and Stability

Julia Shifman, Hebrew University of Jerusalem, Israel
Computational Design of Protein-Protein Interactions

Romain Rouet, Garvan Institute of Medical Research, Australia
Short Talk: Stability Engineering of Human Antibody Therapeutics


Following Session is for Cancer Immunology and Immunotherapy (J4)

17:00—19:00
Cancer Vaccines
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Carl H. June, University of Pennsylvania, USA

Cornelia L. Trimble, Johns Hopkins University School of Medicine, USA
Tissue T Cells in HPV Disease

Cornelis J. M. Melief, Leiden University Medical Center, Netherlands
Chemo-Immunotherapy of High Risk HPV Infections

Marieke Griffioen, Leiden University Medical Center, Netherlands
Short Talk: Intercellular Transfer of Natural HLA Class II Ligands Is Mediated by Full Length Proteins with Abundant Cellular Expression that Are Sequestered and Secreted into Microvesicles

David H. Kirn, Jennerex, USA
Targeted Oncolytic and Immunotherapeutic Viruses: Emerging Multi-Mechanistic Biologics for Cancer

19:00—20:00
Social Hour with Lite Bites

19:30—22:00
Poster Session 2


WEDNESDAY, JANUARY 30

06:45—08:00
Breakfast

07:30—08:00
Poster Setup

08:00—17:00
Poster Viewing

08:00—11:00
Modulating the Activity of Growth Factor Receptors
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Karl Dane Wittrup, Massachusetts Institute of Technology, USA

Ermanno Gherardi, University of Pavia, Italy
Structure/Function and Therapeutic Targeting of HGF/SF and MET

Andreas G. Plückthun, University of Zürich, Switzerland
Engineering Receptor Ligands for Powerful Cellular Responses

Yosef Yarden, Weizmann Institute of Science, Israel
Antibodies to EGFR Family as Drugs

Carlos F. Barbas III, The Scripps Research Institute, USA
Multifunctional and Multi-Specific Antibodies: Single-Protein Combination Therapeutics

Klaus Koefoed, Symphogen A/S, Denmark
Short Talk: In vitro Comparison of EGFR/Her3 Targeting Antibody Mixtures and Bispecific MEHD7945A Analogue Shows More Efficacious Inhibition by Mixtures, Even Under Conditions Mimicking Cancer Resistance


Following Session is for Cancer Immunology and Immunotherapy (J4)

08:00—11:15
Adoptive Cellular Therapy
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Laurence Zitvogel, Institut Gustave Roussy, France

Stanley R. Riddell, Fred Hutchinson Cancer Research Center, USA
Chimeric Antigen Receptor Design and T Cell Subsets in Adoptive Therapy

Kazuhiro Kakimi, University of Tokyo Hospital, Japan
Short Talk: Autologous gammadelta T Cell Transfer Therapy for the Treatment of Solid Cancer

Nicholas P. Restifo, NCI, National Institutes of Health, USA
Memory T Cells Precede Effector Cells: Why it Matters for ACT

Catherine M. Bollard, Baylor College of Medicine, USA
T Cell Therapies for EBV+ Lymphomas – Where Have We Come From and Where Are We Going?

Yanxia Guo, Dartmouth College, USA
Short Talk: Retinoic Acid-Rich Microenvironment Provides Clonal Survival Cues for Tumor and Bacteria-Specific CD8+ T Cells

Robert S. Negrin, Stanford University, USA
Immunobiology of Allogeneic Hematopoietic Cell Transplantation

09:20—09:40
Coffee Break

11:00—12:00
Lunch

12:00—14:30
Poster Session 3

14:30—16:30
Workshop 2: Enhancing Effector Functions and Extending Half-Life

* Henry B. Lowman, CytomX Therapeutics, Inc., USA

Javier Chaparro-Riggers, Rinat-Pfizer Inc., USA
Improving PK and Cholesterol Lowering by a pH-Sensitive Anti-PCSK9-Antibody

Jonathan Sockolosky, University of California, San Francisco, USA
Engineering FcRn-Mediated Recycling and Transcytosis in Recombinant Proteins by Short Terminal Peptide Extensions

Tomoyuki Igawa, Chugai Pharmaceutical, Japan
Engineered Antibody Fc Variant with Selectively Enhanced FcgammaRIIb Binding Over Both FcgammaRIIaR131 and FcgammaRIIaH131

Elizabeth L. Smith, University of California, Berkeley, USA
Antibody Glycoengineering with Aldehyde Tag Technology

Surjit B. Dixit, Zymeworks Inc., Canada
AlbuCORE™ – Structure-Guided Engineering and Design of a Multi-Valent Albumin Scaffold


Following Session is for Cancer Immunology and Immunotherapy (J4)

14:30—16:30
Workshop: Advances in Cancer Immunology

* Wolf-Hervé Fridman, Cordeliers Research Centre, France

Sally Amos, BC Cancer Agency, Canada
Human Bilateral Breast Cancer: A Unique Opportunity to Examine Behaviors of Tumor-Infiltrating Lymphocytes

Sarah Q. Crome, University Health Network, Canada
Regulatory Natural Killer Cells Inhibit Anti-Tumour T Cells

Connie Duong, Peter MacCallum Cancer Centre, Australia
Generating Stronger T Cells for Adoptive Immunotherapy

Daniel T. Fisher, Roswell Park Cancer Institute, USA
Thermal Activation of IL-6 Trans-Signaling Licenses Mouse and Human Tumor Microvascular Gateways for Trafficking of Cytotoxic T Cells

Richard P. Junghans, Roger Williams Hospital, USA
Phase I Trial Data in Prostate Cancer Suggest Critical Role for IL2 Adjunctive Co-Therapy for Successful Suppression of Solid Tumor with Designer T Cells

Brian Ruffell, Oregon Health & Science University, USA
Macrophages Regulate Response to Chemotherapy in Mammary Carcinomas

16:30—17:00
Coffee Available

17:00—19:15
Bispecific and Multispecific Targeting Agents
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Paul Carter, Genentech, Inc., USA

H. Kaspar Binz, Molecular Partners, Switzerland
Exploiting Novel Therapeutic Mechanisms Using Multi-Specific DARPins

James D. Marks, University of California, San Francisco, USA
Development and Mechanism of Action of mAb Combinations that Potently Neutralize Botlinum Neurotoxin

Lutz Jermutus, MedImmune LLC, UK
A Novel Multi-Mechanistic Monoclonal Antibody Format for Treating Pseudomonas aeruginosa Infections

Janine Schuurman, Genmab, Netherlands
Short Talk: Efficient Generation of Stable Bispecific IgG1 by Controlled Fab-Arm Exchange

David Poon, Zymeworks Inc., Canada
Short Talk: Azymetric™ Scaffold – Optimized Fc Heterodimer for Improved Purity and Stability in the Development of Bispecific Antibodies


Following Session is for Cancer Immunology and Immunotherapy (J4)

17:00—19:00
Metabolism and Cancer
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Stanley R. Riddell, Fred Hutchinson Cancer Research Center, USA

Laurence Zitvogel, Institut Gustave Roussy, France
Role of Type 1 IFN and dsRNA Sensors in the T Cell-Dependent Efficacy of Chemotherapy

Vincenzo Bronte, University of Verona, Italy
Myeloid Derived Suppressor Cells

George C. Prendergast, Lankenau Institute for Medical Research, USA
IDO Pathways and Targeting

Courtney Crane, University of Washington/Seattle Children's Research Institute, USA
Short Talk: Tumor Derived Lactate Dehydrogenase Drives Innate Immune Cell Crosstalk in Patients

19:15—
On Own for Dinner


THURSDAY, JANUARY 31

06:45—08:00
Breakfast

08:00—11:15
Immunomodulatory Antibody Therapies (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* George J. Weiner, University of Iowa, USA

Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
PD-1 Blockade in Cancer Therapy

Li Wang, Dartmouth Medical School, USA
Short Talk: Targeting a Novel Immune Checkpoint Protein VISTA Alters Tumor Microenvironment and Synergizes with Cancer Vaccine to Eradicate Established Melanoma

Nils Lonberg, Bristol-Myers Squibb Company, USA
Development Hurdles for Immuno-Oncology Antibody Drugs

Johannes vom Berg, University of Zürich, Switzerland
Short Talk: Local Interleukin-12 in Combination with Systemic Checkpoint Blockade Leads to T-Cell Dependent Rejection of Advanced Stage Glioma

Patrick A. Baeuerle, Amgen Research (Munich) GmbH, Germany
Immunotherapy with BiTE® Antibodies: Lessons Learned from Blinatumomab

Bent Jakobsen, Immunocore Ltd., UK
IMCgp100: A Bispecific TCR Anti-CD3 Fusion for the Treatment of Malignant Melanoma

09:30—09:50
Coffee Break

11:15—16:30
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

17:00—19:00
Challenges and New Opportunities with Antibody Drugs
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Kerry A. Chester, University College London Cancer Institute, UK

Ryan J. Watts, Genentech, Inc., USA
Engineering Bispecific Blood-Brain Barrier Crossing Antibodies

Leo James, University of Cambridge, UK
Intracellular Immunity and TRIM21

Sripad Ram, University of Texas Southwestern Medical Center, USA
Short Talk: Multifocal Plane Microscopy Reveals Novel Intracellular Trafficking Pathways at the Blood-Brain Barrier with Implications to Antibody Delivery to the Brain


Following Session is for Cancer Immunology and Immunotherapy (J4)

17:00—19:00
Anti-Cancer Antibodies
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Nils Lonberg, Bristol-Myers Squibb Company, USA

George J. Weiner, University of Iowa, USA
Therapeutic Mechanisms of Monoclonal Antibodies

Timo K. van den Berg, Sanquin Research and Landsteiner Laboratory, AMC Amsterdam, Netherlands
Short Talk: CD47-SIRPalpha Interactions Form a Barrier for Antibody-Mediated Tumor Cell Destruction by Phagocytes

Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center, USA
Combined Immunologic and Molecular Therapy for Cancer

Glenn Dranoff, Dana-Farber Cancer Institute, USA
Therapy-Induced Antibody Responses

19:00—20:00
Social Hour with Lite Bites

20:00—23:00
Entertainment


FRIDAY, FEBRUARY 1

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

AbbVie Inc. Educational donation provided by Amgen
Astellas Pharma Inc. Genentech, Inc.

We gratefully acknowledge additional support for this conference from:

BioLegend ImmunoGen, Inc.
Seattle Genetics, Inc.
 

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Genentech, Inc.


Micromet, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Amanda Deem, Assistant Director of Development, Email: AmandaD@keystonesymposia.org,
Phone:+1 970-262-2668

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676